Applied UV Declares Monthly Preferred Stock Dividend

Rhea-AI Summary

Applied UV, Inc. (NASDAQ: AUVI) announced a cash dividend of $0.21875 per share for holders of its 10.5% Series A Cumulative Perpetual Preferred Stock (NASDAQ: AUVIP). This dividend is set for payment on or about February 15, 2023, to shareholders on record as of February 3, 2023. The company specializes in pathogen elimination technology, utilizing narrow-range UVC light for effective surface area and air purification. Its subsidiaries, including SteriLumen, offer advanced products to combat infections across various sectors, including healthcare and commercial environments.

Positive

• Authorized cash dividend of $0.21875 per share enhances shareholder returns.
• Strong focus on pathogen elimination technology positions the company favorably in the market.

Negative

• None.

MOUNT VERNON, N.Y.--(BUSINESS WIRE)-- Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UV’s 10.5% Series A Cumulative Perpetual Preferred Stock.

Holders of the 10.5% Series A Cumulative Perpetual Preferred Stock (Nasdaq: AUVIP) shall receive a cash dividend equal to $0.21875 per share.

The return of capital will be paid on or about February 15, 2023, to respective holders of record at the close of business on February 3, 2023.

About Applied UV

Applied UV, Inc. (“AUVI”) develops and acquires proprietary infection prevention and control technology in the healthcare, commercial & public venues, food transportation/storage, cannabis and education vertical markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). Sterilumen owns and markets a portfolio of products with advanced pathogen elimination technology, branded Airocide® by Sterilumen, Scientific Air™ by Sterilumen, Airoclean™ 420 by Sterilumen, and Lumicide™ by Sterilumen.

Leading organizations globally rely on AUVI’s air purification systems to completely eliminate airborne and surface infections, mold, bacteria, allergens and other contaminants. Our customers include Kaiser Permanente, NY Health+Hospitals, Baptist Health South Florida, Boston Red Sox’s Fenway Park, JetBlue Park, France’s Palace of Versailles, Invited Clubs, Whole Foods, Del Monte Foods, U.S. Department of Veterans Affairs, and more.

NASA used Airocide’s proprietary Photocatalytic Oxidation technology to sanitize the International Space Station.

Scientifically proven to reduce Healthcare Acquired Infections (HAI), Scientific Air™ offers a proprietary 3-stage technology integrating HEPA filters, ultraviolet germicidal light chamber and active carbon substrate.

For information on Applied UV, Inc., and its subsidiaries, please visit the following websites:
https://www.applieduvinc.com/
https://www.sterilumen.com
https://airoclean420.com/

Forward-Looking Statements

The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company’s current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005124/en/

Brett Maas, Managing Principal

Hayden IR

brett@haydenir.com

(646) 536-7331

Source: Applied UV, Inc.

FAQ

What is the dividend amount for AUVI's preferred stock?

The dividend amount for AUVI's 10.5% Series A Cumulative Perpetual Preferred Stock is $0.21875 per share.

When will the dividend for AUVI's preferred stock be paid?

The dividend will be paid on or about February 15, 2023.

Who is eligible to receive the dividend from AUVI?

Holders of record at the close of business on February 3, 2023, are eligible to receive the dividend.

What is Applied UV's primary business focus?

Applied UV focuses on pathogen elimination technology for air purification and surface treatment.